IMARC Group’s report titled “Antisense & RNAi Therapeutics Market Report by Technology (RNA Interference, Antisense RNA), Route of Administration (Intravenous Route, Subcutaneous Route, Intrathecal Route, Pulmonary Delivery, Intraperitoneal Injection, and Others), Application (Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Renal Diseases, Neurodegenerative Disorders, Genetic Disorders, Infectious Diseases, and Others), and Region 2024-2032”. The global antisense & rnai therapeutics market size reached US$ 1.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.25% during 2024-2032.
Global Antisense and RNAi Therapeutics Market Trends:
Antisense and RNAi technologies are being explored for new therapeutic areas beyond traditional applications, including infectious diseases, metabolic disorders, and rare genetic conditions, expanding the market potential. Innovations in delivery systems, such as lipid nanoparticles and conjugation technologies, are improving the stability, specificity, and efficacy of antisense and RNAi therapeutics, overcoming previous challenges. Regulatory agencies are increasingly approving antisense and RNAi therapies, supported by clinical successes and advancements in understanding their mechanisms of action and safety profiles.
Grab a sample PDF of this report: https://www.imarcgroup.com/antisense-rnai-therapeutics-market/requestsample
Factors Affecting the Growth of the Antisense and RNAi Therapeutics Industry:
- Advancements in Biotechnology and Molecular Biology:
Innovations in molecular biology are leading to a deeper understanding of how genes are expressed and regulated within cells. This knowledge is critical for developing antisense and RNAi therapies that can specifically target and modulate gene expression. Cutting-edge biotechnological techniques enable the design of more effective and specific antisense oligonucleotides and RNAi molecules. These innovations improve the ability to silence or modify the expression of disease-related genes with high precision.
- Increasing Prevalence of Genetic Disorders and Chronic Diseases:
Many genetic disorders are caused by mutations or dysregulations in specific genes. Antisense and RNAi therapies can precisely target these genetic abnormalities, offering a potential cure or significant improvement in managing conditions, such as Duchenne muscular dystrophy, spinal muscular atrophy, and certain inherited cancers. Chronic diseases like cardiovascular diseases, diabetes, neurodegenerative disorders, and various types of cancer are becoming more prevalent globally. These conditions often involve complex genetic and molecular pathways that can be modulated using antisense and RNAi therapeutics to slow disease progression or alleviate symptoms.
- Technological Innovations:
Advancements in nanoparticle technology, such as LNPs, are significantly improving the delivery of antisense oligonucleotides and RNAi molecules to target cells. These delivery systems protect the therapeutic agents from degradation, enhance cellular uptake, and enable targeted delivery to specific tissues. The development of conjugation techniques, such as attaching ligands or antibodies to antisense and RNAi molecules, enhances targeted delivery and reduces off-target effects. The creation of novel RNA structures, such as circular RNAs, improves the stability and longevity of RNAi molecules in the bloodstream, enhancing their therapeutic potential.
Explore full report with table of contents: https://www.imarcgroup.com/antisense-rnai-therapeutics-market
Leading Companies Operating in the Global Antisense and RNAi Therapeutics Industry:
- Alnylam Pharmaceuticals Inc.
- Arbutus Biopharma Corporation
- Arrowhead Pharmaceuticals Inc.
- Benitec Biopharma Ltd.
- Bio-Path Holdings Inc.
- Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S)
- Ionis Pharmaceuticals Inc.
- OliX Pharmaceuticals Inc.
- Phio Pharmaceuticals Corp.
- Sarepta Therapeutics Inc.
- Silence Therapeutics
- Sirnaomics Inc
Antisense and RNAi Therapeutics Market Report Segmentation:
By Technology:
- RNA Interference
- siRNA
- miRNA
- Antisense RNA
Antisense RNA represents the largest segment due to its ability to specifically target mRNA, offering precise gene regulation and therapeutic potential across various diseases.
By Route of Administration:
- Intravenous Route
- Subcutaneous Route
- Intrathecal Route
- Pulmonary Delivery
- Intraperitoneal Injection
- Others
Pulmonary delivery accounts for the majority of the market share owing to its direct access to target tissues like lungs, enabling effective treatment of respiratory diseases and enhancing therapeutic outcomes.
By Application:
- Oncology
- Cardiovascular Diseases (CVDs)
- Respiratory Disorders
- Renal Diseases
- Neurodegenerative Disorders
- Genetic Disorders
- Infectious Diseases
- Others
Based on the application, the market has been divided into oncology, cardiovascular diseases (CVDs), respiratory disorders, renal diseases, neurodegenerative disorders, genetic disorders, infectious diseases, and others.
Regional Insights:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America enjoys the leading position in the antisense & RNAi therapeutics market on account of its robust research infrastructure, early adoption of innovative therapies, favorable regulatory environment, and substantial investments in biotechnology and pharmaceutical sectors.
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
